September 7, 2016 : Episode 1

FDA Approvals in CLL and ALL, NDA Accepted in Melanoma, and More

Gina Columbus reports on FDA approvals for blinatumomab in acute lymphoblastic leukemia and ofatumumab in chronic lymphocytic leukemia, encouraging phase III findings with atezolizumab in lung cancer, acceptance of a new drug application for binimetinib in melanoma, and a European approval for crizotinib in lung cancer.

Related Content